Contribution of the Tumor Microenvironment to Metabolic Changes Triggering Resistance of Multiple Myeloma to Proteasome Inhibitors

Virtually all patients with multiple myeloma become unresponsive to treatment with proteasome inhibitors over time. Relapsed/refractory multiple myeloma is accompanied by the clonal evolution of myeloma cells with heterogeneous genomic aberrations, diverse proteomic and metabolic alterations, and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Schwestermann, Jonas, Besse, Andrej, Driessen, Christoph, Besse, Lenka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178120/
https://www.ncbi.nlm.nih.gov/pubmed/35692781
http://dx.doi.org/10.3389/fonc.2022.899272

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9178120/
https://www.ncbi.nlm.nih.gov/pubmed/35692781
http://dx.doi.org/10.3389/fonc.2022.899272

Ejemplares similares